Patents Examined by Tori M Strong
-
Patent number: 8946200Abstract: The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants and/or mechanical shear.Type: GrantFiled: November 2, 2006Date of Patent: February 3, 2015Assignee: Southwest Research InstituteInventors: Joseph A McDonough, Hong Dixon
-
Patent number: 8933111Abstract: The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.Type: GrantFiled: February 14, 2013Date of Patent: January 13, 2015Assignee: Theravance Biopharma R&D IP, LLCInventor: Miroslav Rapta
-
Patent number: 8906929Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.Type: GrantFiled: August 5, 2013Date of Patent: December 9, 2014Assignee: Bristol-Myers Squibb CompanyInventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
-
Patent number: 8906951Abstract: The invention relates to methods for treating pruritus with an NK-1 receptor antagonist. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonist.Type: GrantFiled: June 24, 2013Date of Patent: December 9, 2014Assignee: Tigercat Pharma, Inc.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 8889627Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.Type: GrantFiled: October 11, 2012Date of Patent: November 18, 2014Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Hussein Hallak, Nora Tarcic, Joel Flaxman Kaye
-
Patent number: 8853217Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.Type: GrantFiled: September 28, 2012Date of Patent: October 7, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, Pierre-Henri Storck, John Studley, Francoise Yvonne Theodora Marie Pierard
-
Patent number: 8853227Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.Type: GrantFiled: June 20, 2011Date of Patent: October 7, 2014Assignee: Tosk, IncorporatedInventors: William A. Garland, Brian D. Frenzel, Travis Karg
-
Patent number: 8846686Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-1: wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.Type: GrantFiled: September 28, 2012Date of Patent: September 30, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, Pierre-Henri Storck, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Paul Angell, Robert Michael Hughes, David Andrew Siesel, Armando Urbina, Carl Zwicker, Nicholas LoConte, Timothy E. Barder
-
Patent number: 8815874Abstract: The invention provides a pyrazolopyrimidine derivative of formula (I), wherein, for example, R1 represents —NR1aR1b (wherein R1a and R1b are the same or different and each is a hydrogen atom or aralkyl), R2 represents formula (Ya) [wherein k and m each represents an integer of 0-2, n represents an integer of 0-4, L represents a single bond, R5 represents halogen, R6 represents aryl, X represents —CR8 (wherein R8 represents a hydrogen atom), and R7 represents a hydrogen], R3 represents —SO2R13a [wherein R13a represents lower alkoxy, —NR13dC(?O)R13e (wherein R13d represents a hydrogen atom, and R13e represents lower alkyl)], and R4 represents a hydrogen atom, or a pharmaceutically acceptable salt thereof. The invention also provides a medicament containing the pyrazolopyrimidine derivative, as well as a method of using the pyrazolopyrimidine derivative to prevent and/or treat skin diseases.Type: GrantFiled: March 4, 2011Date of Patent: August 26, 2014Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Keisuke Yamamoto, Seiji Aratake, Kazuki Hemmi
-
Patent number: 8802728Abstract: Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.Type: GrantFiled: January 13, 2012Date of Patent: August 12, 2014Assignee: Eli Lilly and CompanyInventors: Jean Marie Defauw, Scott Dale Holmstrom, Shuhui Chen, Yang Zhang, Wentao Wu, Xian Peng, Yujuan Ma, Lun Lu
-
Patent number: 8796335Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.Type: GrantFiled: March 27, 2012Date of Patent: August 5, 2014Assignee: Bayer Intellectual Property GmbHInventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva-Maria Becker, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
-
Patent number: 8772331Abstract: A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum. The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.Type: GrantFiled: July 17, 2012Date of Patent: July 8, 2014Assignee: The Trustees of Princeton UniversityInventors: Bonnie L. Bassler, Lee R. Swem, Scott M. Ulrich, Colleen T. O'Loughlin
-
Patent number: 8710049Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.Type: GrantFiled: July 16, 2012Date of Patent: April 29, 2014Assignee: Bristol-Myers Squibb CompanyInventors: William R. Ewing, Yeheng Zhu, Chongqing Sun, Yanting Huang, Maheswaran Sivasamban Karatholuvhu
-
Patent number: 8697756Abstract: The invention relates to compositions containing at least 90% by weight of dimer diol for use in a method for the surgical or therapeutic treatment of the human or animal body, and in particular to the use thereof as a body fluid replacement substance.Type: GrantFiled: July 10, 2012Date of Patent: April 15, 2014Assignee: ACTO e.V.Inventor: Norbert Schrage
-
Patent number: 8680123Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: October 29, 2012Date of Patent: March 25, 2014Assignee: Auspex Pharmaceuticals, IncInventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 8669262Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.Type: GrantFiled: June 26, 2012Date of Patent: March 11, 2014Assignee: Parion Sciences, Inc.Inventor: Michael R. Johnson
-
Patent number: 8633198Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.Type: GrantFiled: September 19, 2012Date of Patent: January 21, 2014Assignee: Nant Holdings IP, LLCInventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
-
Patent number: 8609658Abstract: The invention provides well defined N,N-dialkylalkenyl ester compounds for treating glaucoma or ocular hypertension. The esters of the invention are particularly advantageous due to their stability in aqueous solutions.Type: GrantFiled: July 25, 2012Date of Patent: December 17, 2013Assignee: Allergan, Inc.Inventors: Robert M. Burk, David W. Old
-
Patent number: 8592483Abstract: The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative.Type: GrantFiled: August 3, 2012Date of Patent: November 26, 2013Assignee: Sucampo AGInventor: Ryuji Ueno
-
Patent number: 8574621Abstract: The present invention provides an adhesive patch for the treatment of tinea unguium intended to be applied once a day, comprising terbinafine and/or a pharmacologically acceptable salt thereof in an amount of 3 mg/cm2, wherein the adhesive patch is used so that the terbinafine concentration in nails may be 295±127 ng/mg and the terbinafine concentration in plasma may be 23 pg/mL or less, 8 weeks after the start of application, per cm2 of the patch size.Type: GrantFiled: February 7, 2011Date of Patent: November 5, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Arata Toshimitsu, Naoko Fujita, Toshihiro Kogure